BCA101
Head and Neck Squamous Cell Carcinoma (HNSCC)
Key Facts
About Bicara Therapeutics
Bicara Therapeutics is pioneering a new class of bifunctional biologics that integrate tumor-targeting precision with microenvironment-modulating power to overcome cancer resistance. The company's lead program, BCA101, is advancing through Phase 1/2 clinical trials for head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, and anal cancer. With a strong leadership team of experienced biotech executives and scientists, Bicara is positioned to address significant unmet needs in oncology through its innovative therapeutic approach.
View full company profileAbout Bicara Therapeutics
Bicara Therapeutics is pioneering a new class of bifunctional biologics that integrate tumor-targeting precision with microenvironment-modulating power to overcome cancer resistance. The company's lead program, BCA101, is advancing through Phase 1/2 clinical trials for head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, and anal cancer. With a strong leadership team of experienced biotech executives and scientists, Bicara is positioned to address significant unmet needs in oncology through its innovative therapeutic approach.
View full company profileAbout Bicara Therapeutics
Bicara Therapeutics is pioneering a new class of bifunctional biologics that integrate tumor-targeting precision with microenvironment-modulating power to overcome cancer resistance. The company's lead program, BCA101, is advancing through Phase 1/2 clinical trials for head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, and anal cancer. With a strong leadership team of experienced biotech executives and scientists, Bicara is positioned to address significant unmet needs in oncology through its innovative therapeutic approach.
View full company profileAbout Bicara Therapeutics
Bicara Therapeutics is pioneering a new class of bifunctional biologics that integrate tumor-targeting precision with microenvironment-modulating power to overcome cancer resistance. The company's lead program, BCA101, is advancing through Phase 1/2 clinical trials for head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, and anal cancer. With a strong leadership team of experienced biotech executives and scientists, Bicara is positioned to address significant unmet needs in oncology through its innovative therapeutic approach.
View full company profile